Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Sep;68(3):579–583. doi: 10.1038/bjc.1993.389

Prognostic value of Ki-67 immunolabelling in primary operable breast cancer.

M Railo 1, S Nordling 1, K von Boguslawsky 1, M Leivonen 1, L Kyllönen 1, K von Smitten 1
PMCID: PMC1968381  PMID: 8394732

Abstract

The prognostic value of Ki-67 immunohistochemical labelling was evaluated in 327 operable primary carcinomas of the breast. The follow-up time was up to 4 years (mean 2.7 years). The disease-free survival in Ki-67 positive patients was shorter than in Ki-67 negative patients (P < 0.005). By combining the Ki-67 expression with ER receptors and stage, subgroups with a different disease-free survival were identified. In stage II patients there was a significant difference (P < 0.005) in disease-free survival between Ki-67 positive/ER negative and Ki-67 negative/ER positive patients. In node negative patients there was no such difference. The disease-free survival according to different prognostic factors, stage, ER and node status, were separately examined using a Cox's proportional hazards model. ER (P < 0.0001), the Ki-67 (P < 0.02), tumour size (P < 0.0001) and nodal status (P < 0.006) were independent prognostic factors. We conclude that the potential value of Ki-67 labelling for prognostic evaluation of patients with breast carcinoma is good.

Full text

PDF
579

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnard N. J., Hall P. A., Lemoine N. R., Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol. 1987 Aug;152(4):287–295. doi: 10.1002/path.1711520407. [DOI] [PubMed] [Google Scholar]
  2. Cattoretti G., Becker M. H., Key G., Duchrow M., Schlüter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. doi: 10.1002/path.1711680404. [DOI] [PubMed] [Google Scholar]
  3. Du Toit R. S., Locker A. P., Ellis I. O., Elston C. W., Blamey R. W. Evaluation of the prognostic value of triple node biopsy in early breast cancer. Br J Surg. 1990 Feb;77(2):163–167. doi: 10.1002/bjs.1800770216. [DOI] [PubMed] [Google Scholar]
  4. Fisher B., Bauer M., Wickerham D. L., Redmond C. K., Fisher E. R., Cruz A. B., Foster R., Gardner B., Lerner H., Margolese R. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983 Nov 1;52(9):1551–1557. doi: 10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  5. Fontana D., Bellina M., Gubetta L., Fasolis G., Rolle L., Scoffone C., Porpiglia F., Colombo M., Tarabuzzi R., Leonardo E. Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J Urol. 1992 Oct;148(4):1149–1151. doi: 10.1016/s0022-5347(17)36845-3. [DOI] [PubMed] [Google Scholar]
  6. Gasparini G., Pozza F., Meli S., Reitano M., Santini G., Bevilacqua P. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res. 1991 Nov-Dec;11(6):2015–2021. [PubMed] [Google Scholar]
  7. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15;31(1):13–20. doi: 10.1002/ijc.2910310104. [DOI] [PubMed] [Google Scholar]
  8. Granata G., Coradini D., Cappelletti V., Di Fronzo G. Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer. 1991;27(8):970–972. doi: 10.1016/0277-5379(91)90260-k. [DOI] [PubMed] [Google Scholar]
  9. Kallioniemi O. P., Hietanen T., Mattila J., Lehtinen M., Lauslahti K., Koivula T. Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol. 1987 Mar;23(3):277–282. doi: 10.1016/0277-5379(87)90071-x. [DOI] [PubMed] [Google Scholar]
  10. Locker A. P., Birrell K., Bell J. A., Nicholson R. I., Elston C. W., Blamey R. W., Ellis I. O. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol. 1992 Jun;18(3):224–229. [PubMed] [Google Scholar]
  11. O'Reilly S. M., Camplejohn R. S., Barnes D. M., Millis R. R., Rubens R. D., Richards M. A. Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol. 1990 Dec;8(12):2040–2046. doi: 10.1200/JCO.1990.8.12.2040. [DOI] [PubMed] [Google Scholar]
  12. Porschen R., Kriegel A., Langen C., Classen S., Hilse M., Lohe B., Hengels K. J., Borchard F. Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki-67 immunostaining. Int J Cancer. 1991 Mar 12;47(5):686–691. doi: 10.1002/ijc.2910470510. [DOI] [PubMed] [Google Scholar]
  13. Silvestrini R., Sanfilippo O., Tedesco G. Kinetics of human mammary carcinomas and their correlation with the cancer and the host characteristics. Cancer. 1974 Oct;34(4):1252–1258. doi: 10.1002/1097-0142(197410)34:4<1252::aid-cncr2820340435>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  14. Slamon D. J., Clark G. M. Amplification of c-erbB-2 and aggressive human breast tumors? Science. 1988 Jun 24;240(4860):1795–1798. doi: 10.1126/science.3289120. [DOI] [PubMed] [Google Scholar]
  15. Thompson S. J., Mellon K., Charlton R. G., Marsh C., Robinson M., Neal D. E. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol. 1992 Jun;69(6):609–613. doi: 10.1111/j.1464-410x.1992.tb15632.x. [DOI] [PubMed] [Google Scholar]
  16. Toi M., Osaki A., Yamada H., Toge T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer. 1991;27(8):977–980. doi: 10.1016/0277-5379(91)90262-c. [DOI] [PubMed] [Google Scholar]
  17. Weikel W., Beck T., Mitze M., Knapstein P. G. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat. 1991 Aug;18(3):149–154. doi: 10.1007/BF01990030. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES